Skip to main content
SpringerLink
Log in

ASO Author Reflections: Improving Outcomes in Diffuse Malignant Peritoneal Mesothelioma: Challenges and Opportunities

  • ASO Author Reflections
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Yan TD, Deraco M, Baratti D, Kusamura S, Elias D, Glehen O, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol. 2009;27(36):6237-42.

    Article  Google Scholar 

  2. Alexander HR Jr, Bartlett DL, Pingpank JF, Libutti SK, Royal R, Hughes MS, et al. Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma. Surgery. 2013;153(6):779-86.

    Article  Google Scholar 

  3. Leinwand JC, Taub RN, Chabot JA, Kluger MD. Two-stage cytoreductive surgery and intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma: predictors of overall survival in an intention-to-treat series. Ann Surg Oncol. 2019. https://doi.org/10.1245/s10434-019-08139-4.

    Article  PubMed  Google Scholar 

  4. Sgarbura O, Gourgou S, Tosi D, Bakrin N, Bouazza N, Delaine S, et al. MESOTIP: Phase II multicenter randomized trial evaluating the association of PIPAC and systemic chemotherapy vs. systemic chemotherapy alone as 1st-line treatment of malignant peritoneal mesothelioma. Pleura Peritoneum. 2019;4(2):20190010.

    Article  Google Scholar 

  5. Sugahara KN, Scodeller P, Braun GB, de Mendoza TH, Yamazaki CM, Kluger MD, et al. A tumor-penetrating peptide enhances circulation-independent targeting of peritoneal carcinomatosis. J Control Release. 2015;212:59-69.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Gastrointestinal and Endocrine Surgery, Department of Surgery, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, USA

    Joshua C. Leinwand MD, MSE & Michael D. Kluger MD, MPH

Authors
  1. Joshua C. Leinwand MD, MSE
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael D. Kluger MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael D. Kluger MD, MPH.

Ethics declarations

Disclosures

The authors report no conflicts of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

ASO Author Reflections is a brief invited commentary on the article, “Two-Stage Cytoreductive Surgery and Intraperitoneal Chemotherapy for Diffuse Malignant Peritoneal Mesothelioma: Predictors of Overall Survival in an Intention-to-Treat Series.” Ann Surg Oncol. (2019). https://doi.org/10.1245/s10434-019-08139-4.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Leinwand, J.C., Kluger, M.D. ASO Author Reflections: Improving Outcomes in Diffuse Malignant Peritoneal Mesothelioma: Challenges and Opportunities. Ann Surg Oncol 27 (Suppl 3), 742–743 (2020). https://doi.org/10.1245/s10434-020-08286-z

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-020-08286-z

Search

Navigation